Skip to main content
    B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.60
    +0.09 (+2.56%)

    Market Cap: $245.04M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(12/29)
    Avg Surprise
    -7.53%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.46
    Range$-0.65 - $-0.04
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.50+8.1%
    60d ago$-0.49+7.0%
    30d ago$-0.49+7.0%
    7d ago$-0.50+8.5%
    Current$-0.46
    Revenue Consensus
    $12M
    Range$598000 - $34M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.78
    Range$-1.13 - $0.33
    8 analysts
    Revenue Consensus
    $-6132800
    Range$-21000000 - $14M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.78---
    Sep 26EST
    		-$-0.46---
    Jun 26
    Reported Jul 30
    		$-0.72$-0.37-94.59%Miss+36.8%
    Mar 26
    Reported Apr 30
    		$-0.87$-0.67-29.85%Miss+1.1%
    Dec 25
    Reported Mar 17
    		$-0.29N/A+69.06%Beat+64.4%
    Sep 25
    Reported Oct 30
    		$-0.85$-1.07+20.56%Beat-18.1%
    Jun 25
    Reported Aug 8
    		$-1.14$-0.93-22.58%Miss-48.1%
    Mar 25
    Reported May 1
    		$-0.88$-0.85-3.53%Miss-41.9%
    Dec 24
    Reported Feb 25
    		$-0.81$-0.85+4.59%Beat+29.8%
    Sep 24
    Reported Oct 31
    		$-0.72$-0.78+7.69%Beat+42.9%
    Jun 24
    Reported Aug 6
    		$-0.77$-1.11+30.63%Beat+45.4%
    Mar 24
    Reported May 2
    		$-0.62$-1.21+48.76%Beat+52.3%
    Dec 23
    Reported Feb 20
    		$-1.16$-1.23+5.69%Beat-14.9%
    Sep 23
    Reported Nov 2
    		$-1.26$-1.06-18.87%Miss-31.3%
    Jun 23
    Reported Aug 3
    		$-1.41$-1.07-31.78%Miss-56.7%
    Mar 23
    Reported May 4
    		$-1.30$-0.96-35.42%Miss-39.8%
    Dec 22
    Reported Feb 28
    		$-1.01$-1.06+4.72%Beat-60.3%
    Sep 22
    Reported Nov 3
    		$-0.96$-0.91-5.49%Miss-62.7%
    Jun 22
    Reported Aug 4
    		$-0.90$-0.81-11.11%Miss-21.6%
    Mar 22
    Reported May 5
    		$-0.93$-0.72-29.17%Miss-27.4%
    Dec 21
    Reported Mar 1
    		$-0.63$-0.61-3.28%Miss+24.1%
    Sep 21
    Reported Nov 4
    		$-0.59$-0.63+6.35%Beat-13.5%
    Jun 21
    Reported Aug 5
    		$-0.74$-0.67-10.45%Miss-10.4%
    Mar 21
    Reported May 6
    		$-0.73$-0.71-2.82%Miss-15.9%
    Dec 20
    Reported Mar 11
    		$-0.83$-0.47-76.60%Miss-232.0%
    Sep 20
    Reported Nov 5
    		$-0.52$-0.53+1.89%Beat+1.9%
    Jun 20
    Reported Aug 5
    		$-0.67$-0.46-45.65%Miss-1.5%
    Mar 20
    Reported May 7
    		$-0.63$-0.38-65.79%Miss-40.0%
    Dec 19
    Reported Mar 10
    		$-0.25N/A+51.92%Beat+67.9%
    Sep 19
    Reported Nov 7
    		$-0.53$-0.69+23.19%Beat-41.5%
    Jun 19
    Reported Aug 8
    		$-0.66$-0.62-6.45%Miss-246.3%
    Mar 19
    Reported May 23
    		$-0.45N/AN/ABeat-19.7%
    Sep 18
    Reported Dec 21
    		$-0.78$0.00N/AMiss-
    Jun 18
    Reported Jun 30
    		$-0.37N/AN/ABeat-
    Mar 18
    Reported Mar 31
    		$-0.19N/AN/ABeat-
    Dec 17
    Reported Dec 31
    		$-0.38N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.32EV/EBITDAN/A
    Price/FCF-1.20xFCF Yield-83.23%
    Profitability
    Profit Margin0.00%Operating Margin-8674.00%
    ROE-32.30%ROIC-35.98%
    Financial Health
    Debt/Equity0.03xInterest Coverage-976.62x
    Current Ratio12.08xQuick Ratio12.08x
    Trading Statistics
    Beta1.68Avg Volume475.38K
    52-Week High$9.0852-Week Low$3.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.71
    SMA 20$3.69
    SMA 50$3.93
    SMA 200$4.73
    EMA 10$3.68
    EMA 20$3.73
    EMA 50$3.87
    EMA 200$4.74

    MACD

    Line: -0.07Signal: -0.07Hist: 0.00

    ADX

    ADX: 13.3+DI: 17.1-DI: 23.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down64.0
    PSAR$3.44

    Bollinger Bands

    Upper Band$3.96
    Lower Band$3.41
    %B Position1485%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    44.7

    Momentum Oscillators

    Stoch %K35.3
    Stoch %D47.5
    Williams %R-61.9
    ROC (10d)1.1%
    Momentum0.04
    CCI (20d)-108.4
    MFI (14d)46.0

    Volatility Measures

    ATR (14d)$0.20(5.7%)
    StdDev (20d)0.14
    Hist Vol82.0%(High)

    Volume Flow

    VWAP$3.58
    OBV-827.0K
    AD Line-20.9M
    CMF (20d)-0.153

    Volume Metrics

    Avg Vol (20d)483.7K
    Vol Ratio0.8x
    VWMA (20d)$3.73

    Pivot Points

    R3$3.93
    R2$3.84
    R1$3.68
    Pivot Point$3.59
    S1$3.42
    S2$3.33
    S3$3.17

    Advanced Oscillators

    TSI-8.70
    Ultimate Osc39.9
    KST-60.04

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$629,000$887,000$47.95M$11.73M$2.92M$9.98M$3.71M$2.68M$9.36M$19.53M$5.33M$5.35M
    Cost of RevenueN/AN/A$35.06MN/A$71.03M$57.27M$56.07M$45.65M$1.64M$1.66M$1.67M$151.61M
    Gross Profit$629,000$887,000$47.95M$11.73M$-68,109,000$-47,294,000$-52,364,000$-42,972,000$9.36M$19.53M$5.33M$5.35M
    Operating Expenses$55.19M$66.48M$72.61M$77.28M$18.49M$22.91M$15.30M$20.87M$56.01M$51.25M$59.57M$56.15M
    R&D$41.16M$48.90M$51.77M$58.43M$71.03M$59.06M$49.78M$48.27M$40.06M$34.86M$44.70M$39.87M
    SG&A$14.03M$17.57M$20.84M$19.02M$19.24M$21.12M$21.02M$18.26M$16.05M$16.45M$15.05M$15.57M
    Operating Income$-54,559,000$-65,589,000$-24,657,000$-65,551,000$-86,602,000$-70,204,000$-67,663,000$-63,846,000$-46,647,000$-31,716,000$-54,235,000$-50,797,000
    Interest Income$4.36M$4.88M$5.88M$6.70M$7.47M$8.41M$10.30M$10.58M$7.77M$5.62M$6.28M$3.98M
    Interest Expense$44,000$48,000$57,000$44,000$54,000$51,000$52,000$33,000$824,000$821,000$820,000$814,000
    Income Before Tax$-50,243,000$-60,653,000$-18,889,000$-58,895,000$-79,183,000$-61,841,000$-52,951,168$-54,250,000$-39,697,000$-26,913,000$-48,779,000$-47,626,000
    Income Tax Expense$90,000$172,000$1.26M$205,000$-231,000$-1,087,000$-1,082,000$-3,448,000$115,000$-350,000$320,000$2.27M
    Net Income$-50,333,000$-60,825,000$-20,154,000$-59,100,000$-78,952,000$-60,754,000$-51,854,000$-50,802,000$-39,812,000$-26,563,000$-49,099,000$-49,898,000
    EBITDA$-49,132,000$-59,476,000$-17,496,000$-57,095,000$-77,433,000$-60,251,727$-51,195,168$-61,230,660$-37,233,000$-24,434,000$-46,305,000$-45,122,000
    EBIT$-50,199,000$-60,605,000$-18,832,000$-58,851,000$-79,129,000$-61,892,000$-52,899,168$-63,402,660$-38,873,000$-26,092,000$-47,959,000$-46,812,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCYC

    News

    Form 4 BICYCLE THERAPEUTICS PLC For: 7 October By Investing.com

    This article announces the filing of Form 4 for BICYCLE THERAPEUTICS PLC on October 7. It is a brief administrative notice from Investing.com, providing basic information about the filing and its publication details.

    Investing.com India•10/8/26•Neutral

    Corrected 356-share sales by Bicycle Therapeutics (BCYC) COO include tax withholding and planned trades.

    Bicycle Therapeutics (BCYC) Chief Operating Officer Jennifer Scott Perry reported amended direct sales totaling 356 ordinary shares on October 5...

    Stock Titan•10/7/26•Neutral

    To cover vesting taxes, Bicycle Therapeutics (BCYC) director sells 3,431 shares.

    Robert Charles Swanton, a director at Bicycle Therapeutics (BCYC), sold 3,431 ordinary shares on October 2, 2026, at a weighted average price of $3.47 per share. This sale was a "sell to cover" transaction...

    Stock Titan•10/7/26•Neutral

    Form 3/A BICYCLE THERAPEUTICS For: Jun 22 Filed by: Thompson Travis Alvin

    This document is an amended Form 3, an initial statement of beneficial ownership of securities, filed by Travis Alvin Thompson...

    StreetInsider•10/7/26•Neutral

    An award agreement required a Bicycle Therapeutics (BCYC) officer to sell 1,572 and 242 shares for taxes.

    Bicycle Therapeutics (BCYC) Chief Product & Supply Chain Officer Michael Charles Ferguson Hannay sold 1,572 ordinary shares on October 2, 2026, and 242 shares on October 5...

    Stock Titan•10/7/26•Neutral

    BCYC Valuation and Fair Value

    P/E
    -1.3x
    P/FCF
    -1.2x
    P/B
    0.5x
    See GNG's fair value

    BCYC Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -8674.0%
    Net margin
    0.0%
    ROIC
    -36.0%
    ROE
    -32.3%
    FCF margin
    -341.7%
    FCF yield
    -83.2%

    BCYC Competitors

    CompanyTicker
    So-Young International IncSY
    SAB Biotherapeutics IncSABS
    BioAge Labs, IncBIOA
    Lifecore Biomedical Inc.LFCR
    Century Therapeutics IncIPSC
    X4 Pharmaceuticals IncXFOR
    Inhibikase Therapeutics IncIKT
    Rocket Pharmaceuticals IncRCKT

    Sector: Healthcare

    BCYC Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    4
    Hold
    3
    Sell
    0
    Strong Sell
    0

    BCYC Bull Case vs Bear Case

    Bull case

    • 66.7% of BCYC's analyst ratings are Buy or Strong Buy.

    Bear case

    • BCYC's quarterly revenue changed -78.5% year over year.

    BCYC Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -6.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.46
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About BCYC

    Does BCYC pay dividends?

    Bicycle Therapeutics Ltd (BCYC) does not currently pay a regular dividend.

    What is BCYC's market cap?

    Bicycle Therapeutics Ltd (BCYC) has a market capitalization of $245.04M with a current stock price of $3.60.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In